From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

BARDA Seeks Antitoxins for Treatment of Inhalational Anthrax

by Global Biodefense Staff
July 9, 2012

The Biomedical Advanced Research and Development Authority (BARDA) has issued a Request for Proposals (RFP) for anthrax antitoxin products to treat individuals with symptomatic anthrax disease resulting from aerosol release of Bacillus anthracis spores.

The solicitation calls for manufacture and delivery to the Strategic National Stockpile anthrax antitoxin suitable for use in humans in a declared emergency or as an FDA-approved product.

Further requirements of the contract include development and maintenance of master cell banks for the production of monoclonal antibody anthrax antitoxins, and collection and storage of human immune plasma for the manufacture of polyclonal anthrax antitoxins.

The RFP supports the Department of Health and Human Services (HHS) plan for acquisition and storage of medical countermeasures that will mitigate injuries caused by exposure to chemical, biological threat agents, physical radiologic and nuclear exposures.

The government contemplates multiple awards of Indefinite Delivery Indefinite Quantity (IDIQ) contracts. The anticipated period of performance will be for base period of up to five years or 60 months.

Full details are available under Solicitation Number: RFP-12-100-SOL-00026. The deadline to submit proposals is July 30, 2012.

From Our Partners
Tags: AnthraxAntitoxinsASPRBARDABioterrorismHHSRequest for ProposalsStrategic National Stockpile

Related Posts

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps
Outbreak News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies
Biosurveillance

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC